Orexo nabs regulatory win for fast-dissolving opioid dependence therapy

Orexo (STO:ORX) said today that the European Medicines Agency granted marketing authorization for its Zubsolv rapidly-disintegrating treatment for opioid dependence. The buprenorphine and naloxone sublingual tablet is the first to be approved in Europe with six different strengths, according to the Sweden-based company. Get the full story at our sister site, Drug Delivery Business News. The post Orexo nabs regulatory win for fast-dissolving opioid dependence therapy appeared first on MassDevice.
Source: Mass Device - Category: Medical Devices Authors: Tags: Pharmaceuticals Regulatory/Compliance Wall Street Beat Orexo AB Source Type: news